.
.
(aka “ambien”)
.
.
-short-acting ‘non-benzodiazepine hypnotic’ of the ‘imidazopyridine’ class-
.
(‘zaleplon’ and ‘zolpidem’ both are agonists at the GABA A α 1 subunit)
(due to its selective binding, ‘zolpidem’ has very weak ‘anxiolytic’, ‘myorelaxant’, and ‘anticonvulsant’ properties but very strong ‘hypnotic’ properties)
(‘zolpidem’ binds with high affinity and acts as a full agonist at the α1-containing GABAA receptors, about 10-fold lower affinity for those containing the α2– and α3– GABAA receptor subunits, and with no appreciable affinity for α5 subunit-containing receptors)
(ω1 type GABAA receptors are the α1-containing GABAA receptors and ω2 GABAA receptors are the α2-, α3-, α4-, α5-, and α6-containing GABAA receptors)
(ω1 GABAA receptors are found primarily in the brain, whereas ω2 receptors are found primarily in the ‘spine’)
(thus, ‘zolpidem’ has a preferential binding for the GABAA-benzodiazepine receptor complex in the brain but a low affinity for the GABAA-benzodiazepine receptor complex in the spine)
(like the vast majority of benzodiazepine-like molecules, ‘zolpidem’ has no affinity for α4 and α6 subunit-containing receptors)
(‘zolpidem’ positively modulates GABAA receptors, it is presumed by increasing the GABAA receptor complex’s apparent affinity for GABA without affecting desensitization or peak current)
(like ‘zaleplon’ (aka ‘sonata’), ‘zolpidem’ may increase ‘slow wave sleep’ but cause no effect on ‘stage 2 sleep’)
.
(a meta-analysis of the randomized, controlled, clinical trials that compared ‘benzodiazepines’ against ‘nonbenzodiazepines’ such as ‘zolpidem’ has shown few consistent differences between ‘zolpidem’ and ‘benzodiazepines’ in terms of…)
‘sleep onset latency’
.
‘total sleep duration’
.
‘number of awakenings’
.
‘quality of sleep’
.
‘adverse events’
.
‘tolerance’
.
‘rebound insomnia’
.
‘daytime alertness’
.
.
.
.
.
.
💕💝💖💓🖤💙🖤💙🖤💙🖤❤️💚💛🧡❣️💞💔💘❣️🧡💛💚❤️🖤💜🖤💙🖤💙🖤💗💖💝💘
.
.
*🌈✨ *TABLE OF CONTENTS* ✨🌷*
.
.
🔥🔥🔥🔥🔥🔥*we won the war* 🔥🔥🔥🔥🔥🔥